MRUS
Merus·NASDAQ
--
--(--)
Market Open: --
--
--(--)
Pre-Market: --
Signals Analysis
Bullish signal 2
Bearish signal 2
Ample Liquidity
High Gross Profit Margin
EPS Below Expectations
Revenue Below Expectations
Key Stats
0.0000DAY`S RANGE0.0000
0.000052 WK RANGE0.0000
0.0000
0.0000
--
--
--
--
--
--
--
--
--
--
--
--
--
--
0.0000
0.0000
0.0000
0.0000
About MRUS
Merus N.V.
A clinical-stage oncology company that developing innovative, full-length multispecific antibodies (Biclonics® and Triclonics®)
Uppsalalaan 17, 3584 CT Utrecht, The Netherlands
--
Merus N.V. was established under Dutch law on June 16, 2003. The company is a clinical-stage immuno-oncology company developing innovative bispecific antibody therapies. Its pipeline of full-length human bispecific antibody candidates, which they call biclonics, is generated from their technology platform.
Company Financials
EPS
MRUS has released its 2025 Q2 earnings. EPS was reported at -2.23, versus the expected -1.15, missing expectations. The chart below visualizes how MRUS has performed over recent quarters, highlighting trends in earnings surprises.
Revenue & Expenses
MRUS has released its 2025 Q3 earnings report, with revenue of 12.15M, reflecting a YoY change of 3.21%, and net profit of -95.52M, showing a YoY change of 4.39%. The Sankey diagram below clearly presents MRUS's revenue sources and cost distribution.
Forecast
Wall Street Opinions
Price Target
Volume Profile
Trade Flow Insight
Seasonals
Community Forum
Loading...
Related News
No articles available
